Algernon Pharmaceuticals Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Stock Symbol
  • AGN
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.06
  • (As of Friday Closing)

Algernon Pharmaceuticals General Information

Description

Algernon Pharmaceuticals Inc is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough, and COVID-19. The company operates in two reportable segments being the development of repurposed therapeutic drugs in Canada and the facilitation of the company's lead drug candidates into off-label phase II clinical trials (humans) in Australia. Its business model is capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

Contact Information

Formerly Known As
Breathtec Biomedical
Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
CNQ
Primary Office
  • 700 West Pender Street
  • Suite 915
  • Vancouver, British Columbia V6C 1G8
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Algernon Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.06 $0.06 $0.06 - $0.42 $10.8M 167M 161K -$0.06

Algernon Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-May-2021 FY 2020 31-Aug-2020 FY 2019 31-Aug-2019 FY 2018 31-Aug-2018
EV 18,236 21,713 4,261 4,307
Revenue 0 0 0 0
EBITDA (8,117) (6,368) (1,414) (710)
Net Income (8,095) (6,342) (1,430) (734)
Total Assets 9,625 9,803 3,994 1,096
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Algernon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Algernon Pharmaceuticals‘s full profile, request access.

Request a free trial

Algernon Pharmaceuticals Patents

Algernon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3105834-A1 Compounds for treatment of inflammatory bowel disease and methods thereof Pending 06-Jul-2018 0000000000
US-20210290566-A1 Compositions and methods for treating non-alcoholic steatohepatitis Pending 06-Jul-2018 0000000000
US-20210290604-A1 Compounds for treatment of inflammatory bowel disease and methods thereof Pending 06-Jul-2018 000000000
EP-3817746-A1 Compounds for treatment of inflammatory bowel disease and methods thereof Pending 06-Jul-2018 0000000000
EP-3813817-A1 The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease Pending 27-Jun-2018 A61K31/167

Algernon Pharmaceuticals Executive Team (8)

Name Title Board Seat Contact Info
Christopher Moreau Chief Executive Officer
Michael Sadhra Chief Financial Officer
Ahmad Khalil MD Chief Medical Officer
Rajpaul Attariwala Ph.D Lead Engineer
You’re viewing 4 of 8 executive team members. Get the full list »

Algernon Pharmaceuticals Board Members (1)

Name Representing Role Since
Howard Gutman Algernon Pharmaceuticals Board Member 000 0000
To view Algernon Pharmaceuticals’s complete board members history, request access »

Algernon Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 0000000000000 22-Oct-2018 000000000000000000 00.000 Drug Discovery 00000000000 000000
To view Algernon Pharmaceuticals’s complete acquisitions history, request access »